全文获取类型
收费全文 | 35229篇 |
免费 | 2209篇 |
国内免费 | 95篇 |
专业分类
耳鼻咽喉 | 419篇 |
儿科学 | 926篇 |
妇产科学 | 872篇 |
基础医学 | 6313篇 |
口腔科学 | 943篇 |
临床医学 | 3320篇 |
内科学 | 6604篇 |
皮肤病学 | 863篇 |
神经病学 | 3144篇 |
特种医学 | 1635篇 |
外国民族医学 | 2篇 |
外科学 | 5335篇 |
综合类 | 219篇 |
一般理论 | 14篇 |
预防医学 | 1922篇 |
眼科学 | 829篇 |
药学 | 2301篇 |
中国医学 | 70篇 |
肿瘤学 | 1802篇 |
出版年
2022年 | 204篇 |
2021年 | 512篇 |
2020年 | 314篇 |
2019年 | 496篇 |
2018年 | 577篇 |
2017年 | 522篇 |
2016年 | 644篇 |
2015年 | 642篇 |
2014年 | 898篇 |
2013年 | 1306篇 |
2012年 | 1752篇 |
2011年 | 1766篇 |
2010年 | 1102篇 |
2009年 | 1126篇 |
2008年 | 1732篇 |
2007年 | 1837篇 |
2006年 | 1828篇 |
2005年 | 1824篇 |
2004年 | 1572篇 |
2003年 | 1537篇 |
2002年 | 1552篇 |
2001年 | 737篇 |
2000年 | 650篇 |
1999年 | 650篇 |
1998年 | 380篇 |
1997年 | 333篇 |
1996年 | 325篇 |
1995年 | 284篇 |
1994年 | 255篇 |
1993年 | 245篇 |
1992年 | 339篇 |
1991年 | 392篇 |
1990年 | 341篇 |
1989年 | 335篇 |
1988年 | 329篇 |
1987年 | 294篇 |
1986年 | 307篇 |
1985年 | 320篇 |
1984年 | 256篇 |
1983年 | 221篇 |
1982年 | 197篇 |
1981年 | 182篇 |
1980年 | 164篇 |
1979年 | 248篇 |
1978年 | 185篇 |
1977年 | 180篇 |
1975年 | 178篇 |
1974年 | 202篇 |
1973年 | 177篇 |
1972年 | 168篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
2.
3.
4.
5.
6.
7.
Daniel J. Snyder Thomas R. Kroshus Aakash Keswani Evan B. Garden Karl M. Koenig Kevin J. Bozic David S. Jevsevar Jashvant Poeran Calin S. Moucha 《The Journal of arthroplasty》2019,34(4):613-618
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献8.
Die Anaesthesiologie - Das Management des schwierigen Atemwegs ist eine präklinische Schlüsselqualifikation. Für Notärzte mit hohem Erfahrungsgrad im Atemwegsmanagement sind... 相似文献
9.
10.
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. 总被引:1,自引:0,他引:1
Samer Ezziddin Timur Logvinski Charlotte Yong-Hing Hojjat Ahmadzadehfar Hans-Peter Fischer Holger Palmedo Jan Bucerius Michael J Reinhardt Hans-Jürgen Biersack 《Journal of nuclear medicine》2006,47(2):223-233
Radiolabeled octreotide analogs (Oct) and metaiodobenzylguanidine (MIBG) offer 2 different approaches for imaging and targeting metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). Despite successful establishment of the revised World Health Organization (WHO) classification, which distinguishes between low- and high-grade malignant GEP-NET, there is a lack of scintigraphic studies comparing uptake behavior on the basis of this categorization. This study aims to define predisposing factors of tracer uptake for both imaging principles implementing the updated tumor criteria of the current WHO classification. METHODS: Fifty-seven consecutive patients with histologically confirmed metastatic GEP-NET evaluated with both 111In-pentetreotide and 123I/131I-MIBG scintigraphy were included in this study. Intensity of tracer uptake was graded according to the different metastatic regions. Patients were classified as overall positive when avid uptake in the clinically relevant tumor lesions was present. Correlation was tested between the proportion of positive patients and tumor origin, function, and malignancy. RESULTS: Overall, 52 patients (91.2%) were Oct positive and 28 patients (49.1%) were MIBG positive. The proportion of tracer-positive patients was significantly higher (P < 0.05) in low-grade malignant tumors for both tracers and in functioning as well as in gastroenteral NET for MIBG. Five patients were negative for both tracers. None of the Oct-negative patients proved to be MIBG positive. CONCLUSION: Oct affinity is observed with high frequency throughout the subgroups of metastatic GEP-NET, whereas corresponding MIBG uptake is overall less prevalent and more group dependent. Tumor differentiation significantly impacts both Oct and MIBG uptake, whereas functionality predisposes only for MIBG accumulation. Though clearly inferior to Oct-based radioimaging in most GEP-NET, MIBG achieves a remarkable rate of radioligand accumulation in functioning midgut enterochromaffin cell metastases (>80% of patients positive). These results may have implications for patient management and potentially for selection and performance of targeted therapy. 相似文献